Evidence map›Paper›PMID 31942981›Full record

ArticleGlycobiology2020

Characterization and engineering of S100A12-heparan sulfate interactions.

Xiaoxiao Zhang, Chihyean Ong, Guowei Su, Jian Liu, Ding Xu

Open access · bronzeAbstract read
In one paragraph

Article in Glycobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Heparan sulfate selectively inhibits the collagenase activity of cathepsin K.Matrix biology : journal of the International Society for Matrix Biology · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xiaoxiao ZhangDepartment of Oral Biology, The University at Buffalo, Buffalo, New York, 14214, USA.
Chihyean OngDepartment of Oral Biology, The University at Buffalo, Buffalo, New York, 14214, USA.
Guowei SuDivision of Chemical biology and Natural Product, School of Pharmacy, The University of North Carolina, Chapel Hill, NC, 27514, USA.
Jian LiuDivision of Chemical biology and Natural Product, School of Pharmacy, The University of North Carolina, Chapel Hill, NC, 27514, USA.
Ding XuDepartment of Oral Biology, The University at Buffalo, Buffalo, New York, 14214, USA.
University at Buffalo, State University of New York · USUniversity of North Carolina at Chapel Hill · US

Funding

In vitro synthesis of recombinant heparan sulfateR01HL094463 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN, PAWLINSKI, RAFAL L · 2009 to 2021
$5.2M
Developing Heparan Sulfate Glycan ArrayR44GM123792 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI SU, GUOWEI · 2020 to 2021
$2.4M
Heparan Sulfate–Osteoprotegerin Interactions in Bone RemodelingR01AR070179 · NIAMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI XU, DING · 2017 to 2021
$1.7M
Synthesis and Pharmacological Evaluation of Homogenous Ultra-Low Molecular Weight HeparinsR01HL144970 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LIU, JIAN · 2019 to 2021
$946k
NHLBI NIH HHS R01 HL094463NHLBI NIH HHS R01 HL144970NIAMS NIH HHS R01 AR070179NIGMS NIH HHS R44 GM123792
6 · The paper itself

Abstract

S100A12, an EF-hand calcium-binding protein, can be secreted by a variety of cell types and plays proinflammatory roles in a number of pathological conditions. Although S100A12 has been shown to interact with heparan sulfate (HS), the molecular detail of the interaction remains unclear. Here we investigate the structural basis of S100A12-HS interaction and how the interaction is regulated by the availability of divalent cations and the oligomeric states of S100A12. We discovered that S100A12-HS interaction requires calcium, while zinc can further enhance binding by inducing S100A12 hexamerization. In contrast, the apo form and zinc-induced tetramer form were unable to bind HS. Guided by the crystal structures of S100A12, we have identified the HS-binding site of S100A12 by site-directed mutagenesis. Characterization of the HS-binding site of S100A12 allowed us to convert the non-HS-binding apo and tetramer forms of S100A12 into a high affinity HS-binding variant by engineering a single-point mutation. Using a HS oligosaccharide microarray, we demonstrated that the N43K mutant displayed markedly enhanced selectivity toward longer HS oligosaccharides compared to the WT S100A12, likely due to the expanded dimension of the reengineered HS-binding site in the mutant. This unexpected finding strongly suggests that HS-binding sites of proteins might be amenable for engineering.

Indexed as

Protein EngineeringBinding SitesCrystallography, X-RayHeparan SulfateHumansModels, MolecularMutationS100A12 ProteinHeparan SulfateS100A12 ProteinS100A12 protein, humancalciumheparan sulfateoligomerizationprotein engineeringS100

Identifiers

PMID31942981
PMCPMC7305801
OpenAlexW2999193678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.